Arpan Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Arpan Patel has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
A. Agarwal
Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India
1 shared publicationAllison R. Schulman
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA
1 shared publicationB. Nayak
Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India
1 shared publicationCachet Magdolna Wenziger
1 shared publicationChristopher J. Sonnenday
Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA
1 shared publicationDavid Elashoff
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by Fortune Journals in Cardiology and Cardiovascular Medicine
- Vol. 06 (01) , 24-41
Association of Increased Risk of Atherosclerotic Cardiovascular (ASCVD) Event in Chronic Liver Disease Patients with and without Cirrhosis
Background: An area of debate in modern medicine is whether there is an association between cirrhosis and Atherosclerotic Cardiovascular Disease (ASCVD). To address this we conducted a retrospective cohort study composed of the 486,887 US Veterans with liver disease over the period of January 2000 to December 2019 to ascertain whether there is an association between cirrhosis and ASCVD. We further divided the cohort based on a diagnosis of cirrhosis. Cox-Regression, negative binomial and competing risk models were used to investigate the time interval between the first and recurrent ASCVD hospitalization with mortality as a competing event risk. The mean± SD age of the cohort was 58 ± 11 years, 4.6% were female, 63% White, 21% Black. 58% of the cohort had liver disease without a diagnosis of cirrhosis. The incidence of ASCVD hospitalization was much higher in liver patients with diagnosis of cirrhosis (11% vs 6%, p value<0.001). In a non-adjusted model with cirrhosis as the exposure the rate of first ASCVD hospitalization was 1.5 times higher than liver disease in patients without cirrhosis (HR: 1.49 (95%CI: 1.47- 1.50), p <0.001). In a fully adjusted model, the risk was attenuated but remained statistically significant (HR: 1.03 (95% CI:1.02-1.04, p <0.001)). The mean number of ASCVD hospitalizations in a count model was 30% lower in the cirrhosis group (mean count ratio 0.70 (95% CI: 0.68-.072)), due to higher competing risk of all-cause mortality with ASCVD events (0.77 (0.73-0.81)). Conclusion: We demonstrate in this retrospective cohort study that as liver disease progresses to cirrhosis, the risk of ASCVD events increases. We hypothesize that the pro-inflammatory states of liver disease could be a viable explanation for the increased risk of ASCVD events in cirrhosis patients. Further translational studies are needed to confirm this hypothesis.
- 1 January 2022
- Published by Fortune Journals in Cardiology and Cardiovascular Medicine
- Vol. 06 (01) , 24-41
Open AccessAssociation of Increased Risk of Atherosclerotic Cardiovascular (ASCVD) Event in Chronic Liver Disease Patients with and without Cirrhosis
Background: An area of debate in modern medicine is whether there is an association between cirrhosis and Atherosclerotic Cardiovascular Disease (ASCVD). To address this we conducted a retrospective cohort study composed of the 486,887 US Veterans with liver disease over the period of January 2000 to December 2019 to ascertain whether there is an association between cirrhosis and ASCVD. We further divided the cohort based on a diagnosis of cirrhosis. Cox-Regression, negative binomial and competing risk models were used to investigate the time interval between the first and recurrent ASCVD hospitalization with mortality as a competing event risk. The mean± SD age of the cohort was 58 ± 11 years, 4.6% were female, 63% White, 21% Black. 58% of the cohort had liver disease without a diagnosis of cirrhosis. The incidence of ASCVD hospitalization was much higher in liver patients with diagnosis of cirrhosis (11% vs 6%, p value<0.001). In a non-adjusted model with cirrhosis as the exposure the rate of first ASCVD hospitalization was 1.5 times higher than liver disease in patients without cirrhosis (HR: 1.49 (95%CI: 1.47- 1.50), p <0.001). In a fully adjusted model, the risk was attenuated but remained statistically significant (HR: 1.03 (95% CI:1.02-1.04, p <0.001)). The mean number of ASCVD hospitalizations in a count model was 30% lower in the cirrhosis group (mean count ratio 0.70 (95% CI: 0.68-.072)), due to higher competing risk of all-cause mortality with ASCVD events (0.77 (0.73-0.81)). Conclusion: We demonstrate in this retrospective cohort study that as liver disease progresses to cirrhosis, the risk of ASCVD events increases. We hypothesize that the pro-inflammatory states of liver disease could be a viable explanation for the increased risk of ASCVD events in cirrhosis patients. Further translational studies are needed to confirm this hypothesis.
- Open Access
Antegrade removal of biliary stones by use of a hepaticogastrostomy in a patient with altered anatomy
- 21 February 2018
- Published by BMJ in BMJ Case Reports
- Vol. 2018
Gastric and duodenal ischaemia after transarterial chemoembolisation for hepatocellular carcinoma: an unexpected but significant complication
Transarterial chemoembolisation (TACE) is commonly used for unresectable intermediate-stage hepatocellular carcinoma (HCC). TACE is usually well-tolerated. We report a case of a patient who presented with a gastrointestinal bleed from TACE. A 64-year-old man presented with chronic hepatitis C cirrhosis and multifocal bilobar HCC. He had previously undergone multiple TACE sessions, radiofrequency ablation and stereotactic body radiation therapy. In the evening of his TACE procedure, he developed abdominal pain and haematemesis. An oesophagogastroduodenoscopy (OGD) showed non-bleeding oesophageal varices and ulcerations in the stomach and duodenum, with pathology demonstrating mucosal necrosis. The patient recovered and was discharged on omeprazole. While TACE is considered safe with most patients only experiencing postembolisation syndrome, vascular complications have been reported. In our patient, OGD revealed ulcerations, with biopsies confirming ischaemic ulceration. The likely aetiology was seepage of the embolic particles into neighbouring arteries. Patients should be carefully selected for TACE and monitored post procedure.
- 21 February 2018
- Published by BMJ in BMJ Case Reports
- Vol. 2018
Gastric and duodenal ischaemia after transarterial chemoembolisation for hepatocellular carcinoma: an unexpected but significant complication
Transarterial chemoembolisation (TACE) is commonly used for unresectable intermediate-stage hepatocellular carcinoma (HCC). TACE is usually well-tolerated. We report a case of a patient who presented with a gastrointestinal bleed from TACE. A 64-year-old man presented with chronic hepatitis C cirrhosis and multifocal bilobar HCC. He had previously undergone multiple TACE sessions, radiofrequency ablation and stereotactic body radiation therapy. In the evening of his TACE procedure, he developed abdominal pain and haematemesis. An oesophagogastroduodenoscopy (OGD) showed non-bleeding oesophageal varices and ulcerations in the stomach and duodenum, with pathology demonstrating mucosal necrosis. The patient recovered and was discharged on omeprazole. While TACE is considered safe with most patients only experiencing postembolisation syndrome, vascular complications have been reported. In our patient, OGD revealed ulcerations, with biopsies confirming ischaemic ulceration. The likely aetiology was seepage of the embolic particles into neighbouring arteries. Patients should be carefully selected for TACE and monitored post procedure.
- 28 January 2018
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 25 (7) , 771-778
Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection
Summary: Novel direct‐acting antivirals (DAAs) are now the standard of care for the management of hepatitis C virus (HCV) infection. Branded DAAs are associated with high sustained virological response at 12 weeks post‐completion of therapy (SVR12), but are costly. We aimed to assess the efficacy of generic oral DAAs in a real‐life clinical scenario. Consecutive patients with known HCV infection who were treated with generic‐oral DAA regimens (May 2015 to January 2017) were included. Demographic details, prior therapy and SVR12 were documented. Four hundred and ninety patients (mean age: 38.9 ± 12.7 years) were treated with generic DAAs in the study time period. Their clinical presentations included chronic hepatitis (CHC) in 339 (69.2%) of cases, compensated cirrhosis in 120 (24.48%) cases and decompensated cirrhosis in 31 (6.32%) cases. Genotype 3 was most common (n = 372, 75.9%) followed by genotype 1 (n = 97, 19.8%). Treatment naïve and treatment‐experienced (defined as having previous treatment with peginterferon and ribavirin) were 432 (88.2%) and 58 (11.8%), respectively. Generic DAA treatment regimens included sofosbuvir in combination with ribavirin (n = 175), daclatasvir alone (n = 149), ribavirin and peginterferon (n = 80), ledipasvir alone (n = 43), daclatasvir and ribavirin (n = 37), and ledipasvir and ribavirin (n = 6). Overall SVR12 was 95.9% (470/490) for all treatment regimens. SVR12 for treatment naïve and experienced patients was 97.0% (419/432) and 87.9% (51/58), respectively, P = .005. High SVR12 was observed with various regimens, irrespective of genotype and underlying liver disease status. There were no differences in SVR12 with 12 or 24 weeks therapy. No major adverse event occurred requiring treatment stoppage. Generic oral DAAs are associated with high SVR rates in patients with HCV infection in a real‐life clinical scenario.
- 28 January 2018
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 25 (7) , 771-778
Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection
Summary: Novel direct‐acting antivirals (DAAs) are now the standard of care for the management of hepatitis C virus (HCV) infection. Branded DAAs are associated with high sustained virological response at 12 weeks post‐completion of therapy (SVR12), but are costly. We aimed to assess the efficacy of generic oral DAAs in a real‐life clinical scenario. Consecutive patients with known HCV infection who were treated with generic‐oral DAA regimens (May 2015 to January 2017) were included. Demographic details, prior therapy and SVR12 were documented. Four hundred and ninety patients (mean age: 38.9 ± 12.7 years) were treated with generic DAAs in the study time period. Their clinical presentations included chronic hepatitis (CHC) in 339 (69.2%) of cases, compensated cirrhosis in 120 (24.48%) cases and decompensated cirrhosis in 31 (6.32%) cases. Genotype 3 was most common (n = 372, 75.9%) followed by genotype 1 (n = 97, 19.8%). Treatment naïve and treatment‐experienced (defined as having previous treatment with peginterferon and ribavirin) were 432 (88.2%) and 58 (11.8%), respectively. Generic DAA treatment regimens included sofosbuvir in combination with ribavirin (n = 175), daclatasvir alone (n = 149), ribavirin and peginterferon (n = 80), ledipasvir alone (n = 43), daclatasvir and ribavirin (n = 37), and ledipasvir and ribavirin (n = 6). Overall SVR12 was 95.9% (470/490) for all treatment regimens. SVR12 for treatment naïve and experienced patients was 97.0% (419/432) and 87.9% (51/58), respectively, P = .005. High SVR12 was observed with various regimens, irrespective of genotype and underlying liver disease status. There were no differences in SVR12 with 12 or 24 weeks therapy. No major adverse event occurred requiring treatment stoppage. Generic oral DAAs are associated with high SVR rates in patients with HCV infection in a real‐life clinical scenario.